Which glioblastoma patients will respond to immunotherapy? A biomarker may hold answers
Northwestern Medicine scientists have discovered a new biomarker to identify which patients with brain tumors called glioblastomas—the most common and malignant of primary brain tumors—might benefit from immunotherapy.
Nov 29, 2021
0
73